Notably, the overexpression of SET has been associated with poor prognosis, high recurrence rate, and chemoresistance (Cristóbal et al., 2015) in several types of cancer including lung (Liu et al., 2015), glioblastoma (He et al., 2016), breast (Huang et al., 2018), and pancreas (Bhutia et al., 2013). Here, SET is linked to cancer.